US equities
|
NVDA
$239.56
▲+2.40%
SPCX
$169.70
▲+6.76%
MU
$1,061.61
▼-1.24%
TSLA
$380.46
▲+2.66%
SNDK
$1,695.40
▼-1.43%
MSFT
$528.43
▲+2.11%
INTC
$116.40
▼-2.46%
META
$744.03
▲+2.19%
NVDA
$239.56
▲+2.40%
SPCX
$169.70
▲+6.76%
MU
$1,061.61
▼-1.24%
TSLA
$380.46
▲+2.66%
SNDK
$1,695.40
▼-1.43%
MSFT
$528.43
▲+2.11%
INTC
$116.40
▼-2.46%
META
$744.03
▲+2.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Artivion, Inc. Common Stock
(NY:
AORT
)
22.86
+0.55 (+2.44%)
Delayed Quote
Updated: 3:23 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Artivion, Inc. Common Stock
< Previous
1
2
3
4
5
6
Next >
Gapping stocks in Friday's session
↗
May 08, 2026
Via
Chartmill
AORT Q1 Deep Dive: Guidance Reset and Product Launches Shape 2026 Outlook
May 08, 2026
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o...
Via
StockStory
Topics
Economy
Artivion Inc (NYSE:AORT) Stock Slides After Q1 Revenue Miss Despite Earnings Beat
↗
May 07, 2026
Via
Chartmill
Artivion (AORT) Q1 2026 Earnings Transcript
↗
May 07, 2026
Artivion (AORT) Q1 2026 Earnings Transcript
Via
The Motley Fool
Artivion Inc (NYSE:AORT) Shares Drop on Q4 Revenue Miss Despite Earnings Beat
↗
February 12, 2026
Via
Chartmill
Artivion’s (NYSE:AORT) Q1 CY2026 Earnings Results: Revenue In Line With Expectations
May 07, 2026
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o...
Via
StockStory
What To Expect From Artivion’s (AORT) Q1 Earnings
May 05, 2026
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after market close. Here’s what you need to know. Artivion missed analys...
Via
StockStory
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
April 28, 2026
Over the last six months, Artivion’s shares have sunk to $37.03, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 3.9% gain. This was...
Via
StockStory
Topics
Stocks
Supply Chain
1 Stock Under $50 to Own for Decades and 2 We Avoid
April 13, 2026
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
Via
StockStory
Topics
ETFs
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know
April 07, 2026
What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...
Via
StockStory
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion
April 07, 2026
Check out the companies making headlines yesterday: Levi's (NYSE:LEVI): Denim clothing company Levi's (NYSE:LEVI) rose by 2.8% on Monday after investor optim...
Via
StockStory
Why Artivion (AORT) Stock Is Down Today
April 06, 2026
What Happened? Shares of medical device company Artivion (NYSE:AORT) fell 2.1% in the afternoon session after a proposed 2027 federal budget revealed signifi...
Via
StockStory
Topics
Artificial Intelligence
Government
Stocks
1 Healthcare Stock on Our Watchlist and 2 We Find Risky
April 03, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t...
Via
StockStory
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
April 01, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
Via
StockStory
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
March 31, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
March 27, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via
StockStory
Topics
Government
Stocks
3 of Wall Street’s Favorite Stocks We Steer Clear Of
March 23, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via
StockStory
Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To Know
March 06, 2026
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Via
StockStory
Topics
Economy
5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call
February 19, 2026
Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand...
Via
StockStory
Topics
Earnings
Artivion (AORT) Stock Trades Down, Here Is Why
February 13, 2026
Shares of medical device company Artivion (NYSE:AORT) fell 5.8% in the morning session after the company reported mixed fourth-quarter 2025 financial results, with revenues falling short of analyst...
Via
StockStory
AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline
February 13, 2026
Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue...
Via
StockStory
Artivion (AORT) Q4 2025 Earnings Call Transcript
↗
February 12, 2026
Artivion (AORT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
February 12, 2026
Medical device company Artivion (NYSE:AORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year...
Via
StockStory
What To Expect From Artivion’s (AORT) Q4 Earnings
February 10, 2026
Medical device company Artivion (NYSE:AORT) will be reporting results this Thursday afternoon. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
World Trade
2 Stocks Under $50 to Research Further and 1 We Avoid
January 26, 2026
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...
Via
StockStory
1 Profitable Stock with Exciting Potential and 2 Facing Headwinds
January 12, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via
StockStory
1 Healthcare Stock on Our Watchlist and 2 We Ignore
January 04, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also...
Via
StockStory
Topics
Stocks
3 Reasons to Sell AORT and 1 Stock to Buy Instead
January 01, 2026
What a time it’s been for Artivion. In the past six months alone, the company’s stock price has increased by a massive 47.8%, reaching $45.61 per share. This was partly thanks to its solid quarterly...
Via
StockStory
Topics
Supply Chain
1 Safe-and-Steady Stock on Our Watchlist and 2 We Avoid
December 28, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
3 Cash-Producing Stocks with Questionable Fundamentals
December 17, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Topics
Retirement
< Previous
1
2
3
4
5
6
Next >
